IPO round-up: Avinger, HTG Molecular Diagnostics
This article was originally published in Clinica
Executive Summary
A couple of companies managed to sneak in IPO filings before 2014 ended: peripheral vascular disease treatment specialist Avinger and HTG Molecular Diagnostics.